ArticleHepatology (Baltimore, Md.)2025
MASLD/MetALD and mortality in individuals with any cardio-metabolic risk factor: A population-based study with 26.7 years of follow-up.
Article in Hepatology (Baltimore, Md.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Distinct Laboratory and Clinical Features of Metabolic and Alcohol-Related Liver Disease (MetALD): A Systematic Review and Meta-Analysis.Current obesity reports · 2026Pooled it
- Metabolic (dysfunction)-associated fatty liver disease metrics and contributions to liver research.Hepatology international · 2024Pooled it
- Pooled it
- Global epidemiological patterns and disease burden of metabolic dysfunction-associated steatotic liver disease, metabolic dysfunction and alcohol-associated liver disease, and alcohol-associated liver disease.Clinical and molecular hepatology · 2026Review
- Cardiovascular and hepatic outcomes: prognostic differences across MASLD-MetALD-ALD continuum.Clinical and molecular hepatology · 2026Review
- Time-Varying Impact of Steatosis and Alcohol on Mortality: A Marginal Structural Model of the Canadian Longitudinal Study on Aging.Liver international : official journal of the International Association for the Study of the Liver · 2026Article
- Steatotic liver disease in Latin America: current views and perspectives.Nature reviews. Gastroenterology & hepatology · 2026Review
- Frailty may confound the association between MASLD and cardiovascular mortality in people with cardiometabolic risk factors.Cardiovascular diabetology · 2026Article
- The introduction of metabolic alcoholic liver disease: a perspective for UK primary care.The British journal of general practice : the journal of the Royal College of General Practitioners · 2026Article
- Pharmacologic management of metabolic and alcohol-associated liver disease.Metabolism and target organ damage · 2026Article
- Ultrasound-Derived Fat Fraction and Metabolic Parameters in Predicting Panvascular Disease Risk in Metabolic Dysfunction-Associated Steatotic Liver Disease Patients: A Prospective Study.Endocrinology and metabolism (Seoul, Korea) · 2026Article
- Traditional and Modern Predictors of Atherosclerotic Cardiovascular Disease in Patients with T2D and MASLD.Diagnostics (Basel, Switzerland) · 2026Article
- Risk stratification for patients with MASLD based on cardiometabolic risk factors.BMC public health · 2026Observational
- Association between the aMAP risk score and mortality in the MASLD/MetALD/ALD patient population: a cohort study.Frontiers in medicine · 2026Article
- Divergent risk profiles for cause-specific mortality in MASLD and MetALD: a nationwide population-based study.Frontiers in medicine · 2026Article
- Associations of cardiometabolic burden with cardiovascular disease-death transitions in metabolic dysfunction-associated steatotic liver disease: a prospective cohort study using multistate analysis.Frontiers in nutrition · 2026Article
- The association of steatotic liver disease with cardiometabolic criteria and cardiovascular disease risk in a large cohort of people living with human immunodeficiency virus.American journal of preventive cardiology · 2025Article
- Met-ALD and ALD- Does Differentiating These Impact Management and Clinical Outcomes?Current hepatology reports · 2025Article
- Clinical trial design, biomarkers and end points in metabolic and alcohol-related liver disease.Nature reviews. Gastroenterology & hepatology · 2025Review
- Crosstalk Between Metabolic Dysfunction-Associated Steatotic Liver Disease and Atrial Fibrillation: Shared Mechanism, Diagnostic Integration, and Management Implications.Life (Basel, Switzerland) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
BACKGROUND AND
aimsA new term, metabolic dysfunction-associated steatotic liver disease (MASLD), has been proposed by a multi-society expert panel. However, it remains unclear whether hepatic steatosis per se in MASLD contributes to an increased risk of mortality in individuals with any cardio-metabolic risk factor (CMRF), which is also a significant risk factor for increased mortality. This study aimed to compare all-cause and cause-specific mortality between the "MASLD/MetALD" and "no steatotic liver disease (SLD)" groups in individuals with any CMRF. APPROACH AND
resultsA population-based cohort study was conducted using 10,750 participants of the Third National Health and Nutrition Examination Survey. All-cause and cause-specific (cardiovascular, cancer, diabetes, and liver) mortality risks were compared between the "MASLD," "MetALD," and "no SLD" groups using the Cox proportional hazards model with complex survey design weights, adjusted for confounders. Over 26 years, the "MASLD" group did not show significantly increased all-cause (adjusted HR 1.04[95% CI: 0.95-1.14], p = 0.413), cardiovascular (0.88 [0.75-1.04], p = 0.139), or cancer (1.06[0.84-1.33], p = 0.635) mortality risk compared to the "no SLD" group in individuals with any CMRF. The MetALD group was associated with increased all-cause (1.41 [1.05-1.89], p = 0.022), cancer (2.35 [1.33-4.16], p = 0.004), and liver (15.04 [2.96-76.35], p = 0.002) mortality risk compared with the no SLD group. This trend was more pronounced in the MetALD group with advanced fibrosis assessed by Fibrosis-4 (FIB-4).
conclusionsIn individuals with CMRF, the presence of steatotic liver disease (MASLD) alone did not increase the risk of mortality, except in cases with more alcohol consumption (MetALD). Therefore controlling metabolic risk factors and reducing alcohol consumption in people with MASLD or MetALD will be crucial steps to improve long-term health outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.